LONG MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 02:03:48 2024-07-03 pm EDT | ||
| 6.04 EUR | +3.96% |
|
| Current month | -1.95% | ||
| 1 month | -33.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 6.04 | +3.96% |
| 24-07-02 | 5.81 | -3.65% |
| 24-07-01 | 6.03 | -2.11% |
| 24-06-28 | 6.16 | -8.61% |
| 24-06-27 | 6.74 | -0.74% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 02:03 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VE93FP |
| ISIN | DE000VE93FP5 |
| Date issued | 2020-03-17 |
| Strike | 1,281 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.19 € |
|---|---|
| Lowest since issue | 1.18 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,742
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.41%
- Stock Market
- Certificates
- Certificat
